Asish K. Xavier

Asish Xavier serves as the Vice President of Venture Investments at Johnson & Johnson's JJDC since June 2004, where notable achievements include leading investments in a wide array of life sciences companies. Prior roles at JJDC include Principal and Senior Associate in Venture Investments, with contributions to significant acquisitions such as Ilypsa, acquired by Amgen. In addition to investment responsibilities, Asish Xavier holds board positions and board observer roles with multiple firms, including Bright Peak Therapeutics, Capstan Therapeutics, Rondo Therapeutics, Arialys Therapeutics, Verana Health, Paige, and Legend Biotech, which went public in 2020. Educational credentials include an MBA in Finance & Entrepreneurship from The Wharton School, a Postdoctoral Fellowship in Chemistry & Biophysics from The Johns Hopkins University, a Ph.D. in Chemical Engineering from the University of Houston, and a B.Tech in Chemical Engineering from the Indian Institute of Technology, Kanpur.